Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cediranib · AZD-2171

Small molecule · Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4) · developed by ASTRAZENECA

Phase 3 Most advanced trial

AZN Developer

2 Registered trials

What is Cediranib?

Cediranib is an orally bioavailable indole ether quinazoline derivative that inhibits vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1/2/3). By blocking VEGF-signaling and angiogenesis, it suppresses tumor cell growth. It is studied in ovarian, fallopian tube, and renal cell cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-2171, Recentin
Drug type: Small molecule
Targets: VEGFR-1 (FLT1), VEGFR-2 (KDR), VEGFR-3 (FLT4)
Mechanism: Inhibitor of VEGFR-1 (FLT1), VEGFR-2 (KDR) and VEGFR-3 (FLT4)
Pathways: VEGF-signaling, angiogenesis
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: NQU9IPY4K9

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02446600	Phase 3	Fallopian Tube Clear Cell Adenocarcinoma	Active not recruiting	AZN
NCT03741426	Phase 2	Renal Cell Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid TumorOvarian Seromucinous CarcinomaOvarian Serous TumorOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Primary Peritoneal CarcinomaRenal Cell Cancer

Other drugs acting on FLT1 / KDR / FLT4

Nintedanib FDA approved Regorafenib FDA approved Sunitinib FDA approved Sitravatinib Phase 3

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Cediranib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z